Summit Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Summit Therapeutics is Bob Duggan, benoemd in Jul2022, heeft een ambtstermijn van 2.33 jaar. bezit rechtstreeks 74.81% van de aandelen van het bedrijf, ter waarde $ 11.03B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4.5 jaar.

Belangrijke informatie

Bob Duggan

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.3yrs
Eigendom CEO	74.8%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Nov 08

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Oct 04

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Sep 19

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Sep 09

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Aug 17

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Aug 11

Summit to explore additional trial for its bacteria-induced colon infection drug

Jul 14

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Apr 29

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Dec 23

Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator

Jun 22

Summit Therapeutics to join Russell 3000 Index

Jun 08

CEO

Bob Duggan (80 yo)

2.3yrs

Tenure

Mr. Robert W. Duggan, also known as Bob, had been an Interim Principal Financial Officer at Summit Therapeutics Inc. since July 02, 2021. He served as the Co-Chief Executive Officer at Summit Therapeutics...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Duggan	Co-CEO & Executive Chairman	2.3yrs	geen gegevens	74.81% $ 11.0b
Mahkam Zanganeh	Co-CEO, President & Director	2.3yrs	US$20.56m	4.85% $ 714.8m
Manmeet Soni	COO, CFO & Director	1.1yrs	US$23.97m	0.41% $ 60.4m
Dame Davies	Co-Founder	no data	geen gegevens	geen gegevens
Bhaskar Anand	Chief Accounting Officer & Head of Finance	less than a year	geen gegevens	0.018% $ 2.6m
Abby Murphy	Head of Human Resources	1.6yrs	geen gegevens	geen gegevens
Divya Chari	Head of Global Clinical Operations	4.7yrs	geen gegevens	geen gegevens
Dave Gancarz	Chief Business & Strategy Officer	no data	geen gegevens	geen gegevens
Betty Chang	Head of Research	3.4yrs	geen gegevens	geen gegevens
Fong Clow	Chief Biometrics Officer	3.8yrs	geen gegevens	geen gegevens
Shelley Spray	Chief Education & Brand Officer	1.8yrs	geen gegevens	geen gegevens
Juthamas Sukbuntherng	Head of Clinical Pharmacology & DMPK	3.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SMMT wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Duggan	Co-CEO & Executive Chairman	4.9yrs	geen gegevens	74.81% $ 11.0b
Mahkam Zanganeh	Co-CEO, President & Director	4yrs	US$20.56m	4.85% $ 714.8m
Manmeet Soni	COO, CFO & Director	4.9yrs	US$23.97m	0.41% $ 60.4m
Dame Davies	Co-Founder	no data	geen gegevens	geen gegevens
Kenneth Clark	Lead Independent Director	3.1yrs	US$334.65k	geen gegevens
Marcel van den Heuvel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Francesco Muntoni	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roger Patient	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Edith Sim	Member of Scientific Advisory board	no data	geen gegevens	geen gegevens
Bob Sim	Member of Scientific Advisory board	no data	geen gegevens	geen gegevens
Derek Stemple	Member of Scientific Advisory board	no data	geen gegevens	geen gegevens
Jean-Paul Vincent	Member of Scientific Advisory board	no data	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SMMT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Summit Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Recent updates

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?

Summit Therapeutics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market

Summit Therapeutics Inc. Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Summit Therapeutics Inc. announced that it has received $234.945 million in funding

Summit Therapeutics Inc. Announces Data Relating to the HARMONi-2 Trial

Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)

Summit Therapeutics May Have Further Upside From Here

Summit Therapeutics Inc. to Report Q2, 2024 Results on Aug 06, 2024

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 3000E Index

Summit Therapeutics Inc. Appoints Jeff Huber to Its Board of Directors

Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP

Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival

Summit Therapeutics Stock: Plunging Despite A Win?

Summit Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $90 million.

New major risk - Share price stability

Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer

Summit Therapeutics Inc., Annual General Meeting, Jun 14, 2024

Summit Therapeutics Inc. to Report Q1, 2024 Results on May 01, 2024

Less than half of directors are independent

Summit Therapeutics Inc. Appoints Dr. Mostafa Ronaghi to Its Board of Directors

Summit Therapeutics Inc. Appoints Bhaskar Anand as Chief Accounting Officer, Head of Finance, to Serve as Its Principal Accounting Officer

Co-CEO, President & Director recently bought US$411k worth of stock

Summit Therapeutics Inc. Announces Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024

Summit Therapeutics Inc. Announces That Data for Its Novel, Potential First-In-Class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At the 2024 European Lung Cancer Congress (Elcc 2024) in Prague, Czech Republic

New minor risk - Financial position

Summit Therapeutics Inc. to Report Q4, 2023 Results on Feb 20, 2024

Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab At 42Nd Annual J.P. Morgan Healthcare Conference

Co-CEO, President & Director exercised options to buy US$2.1m worth of stock.

Laura Chow Joins Summit Therapeutics Inc. as Senior Vice President of Clinical Development

Summit Therapeutics Inc. to Report Q3, 2023 Results on Nov 07, 2023

Lead Independent Director recently bought US$5.0m worth of stock

Summit Therapeutics Inc. Announces Executive Changes

First half 2023 earnings released: US$1.03 loss per share (vs US$0.38 loss in 1H 2022)

Summit Therapeutics Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

First quarter 2023 earnings released: US$1.43 loss per share (vs US$0.22 loss in 1Q 2022)

Summit Therapeutics Announces First Patient Treated in Phase III Harmoni Clinical Trial Evaluating Ivonescimab (SMT112)

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (Smt112)

Summit Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.41 loss per share (vs US$0.96 loss in FY 2021)

Summit Therapeutics Inc. Appoints Yu (Michelle) Xia as Member of the Board

We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely

Summit Therapeutics Inc. Appoints Alessandra Cesano to Its Board of Directors

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 3Q 2021)

Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole

Summit Therapeutics Inc. Announces Executive Changes

Summit Therapeutics slips on plans to terminate study for lead candidate

Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.27 loss in 2Q 2021)

Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M

Summit Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $99.91 million.

Summit Therapeutics Appoints Maky Zanganeh as Co-CEO

Summit Therapeutics Provides Update on Ridinilazole

Summit to explore additional trial for its bacteria-induced colon infection drug

Summit Therapeutics Inc.(NasdaqGM:SMMT) dropped from Russell 2000 Growth Index

Summit Therapeutics Inc. Appoints Ankur Dhingra as Chief Financial Officer

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.21 loss in 1Q 2021)

Summit Therapeutics Inc., Annual General Meeting, Jun 15, 2022

Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation

Less than half of directors are independent

Less than half of directors are independent

Summit Therapeutics - Disappointing Data But Not An Outright Failure

Summit Therapeutics Inc. Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Summit Therapeutics Inc. Provides Update on Ri-CoDIFy Trials